159 related articles for article (PubMed ID: 29745334)
1. The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment.
Hernando S; Pedraz JL; Igartua M; Hernandez RM
Curr Drug Deliv; 2018; 15(9):1218-1220. PubMed ID: 29745334
[No Abstract] [Full Text] [Related]
2. Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.
Mc Carthy DJ; Malhotra M; O'Mahony AM; Cryan JF; O'Driscoll CM
Pharm Res; 2015 Apr; 32(4):1161-85. PubMed ID: 25446769
[TBL] [Abstract][Full Text] [Related]
3. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
Fu L; Chung R; Shi B
Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery.
Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S
Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427
[TBL] [Abstract][Full Text] [Related]
5. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
Kreuter J
J Nanosci Nanotechnol; 2004 May; 4(5):484-8. PubMed ID: 15503433
[TBL] [Abstract][Full Text] [Related]
6. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
7. Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo.
Chhabra R; Ruozi B; Vilella A; Belletti D; Mangus K; Pfaender S; Sarowar T; Boeckers TM; Zoli M; Forni F; Vandelli MA; Tosi G; Grabrucker AM
CNS Neurol Disord Drug Targets; 2015; 14(8):1041-53. PubMed ID: 26295815
[TBL] [Abstract][Full Text] [Related]
8. Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders.
Singh D; Kapahi H; Rashid M; Prakash A; Majeed AB; Mishra N
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):780-91. PubMed ID: 26107112
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
Dilnawaz F; Sahoo SK
Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the properties of biomolecules for brain targeting of nanoparticulate systems.
Cramer S; Rempe R; Galla HJ
Curr Med Chem; 2012; 19(19):3163-87. PubMed ID: 22612701
[TBL] [Abstract][Full Text] [Related]
11. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
Hanson LR; Frey WH
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002
[TBL] [Abstract][Full Text] [Related]
12. Current approaches to enhance CNS delivery of drugs across the brain barriers.
Lu CT; Zhao YZ; Wong HL; Cai J; Peng L; Tian XQ
Int J Nanomedicine; 2014; 9():2241-57. PubMed ID: 24872687
[TBL] [Abstract][Full Text] [Related]
13. [Opening the brain to new therapies].
Collin L
Med Sci (Paris); 2014 May; 30(5):486-8. PubMed ID: 24939528
[No Abstract] [Full Text] [Related]
14. Nanocomposites for neurodegenerative diseases: hydrogel-nanoparticle combinations for a challenging drug delivery.
Giordano C; Albani D; Gloria A; Tunesi M; Rodilossi S; Russo T; Forloni G; Ambrosio L; Cigada A
Int J Artif Organs; 2011 Dec; 34(12):1115-27. PubMed ID: 22198597
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Gastrodin in rat plasma and CSF after i.n. and i.v.
Wang Q; Chen G; Zeng S
Int J Pharm; 2007 Aug; 341(1-2):20-5. PubMed ID: 17482780
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles as novel carrier for brain delivery: a review.
Agarwal A; Lariya N; Saraogi G; Dubey N; Agrawal H; Agrawal GP
Curr Pharm Des; 2009; 15(8):917-25. PubMed ID: 19275654
[TBL] [Abstract][Full Text] [Related]
17. Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.
Kibathi LW; Bae S; Penzak SR; Kumar P
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):619-635. PubMed ID: 29858835
[TBL] [Abstract][Full Text] [Related]
18. Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies.
Kojima S; Cucuianu A; Takahashi Y; Berindan-Neagoe I; Florian IS; Dima D; Tomuleasa C
Int J Nanomedicine; 2014; 9():3247-8. PubMed ID: 25045259
[No Abstract] [Full Text] [Related]
19. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier.
Dal Magro R; Ornaghi F; Cambianica I; Beretta S; Re F; Musicanti C; Rigolio R; Donzelli E; Canta A; Ballarini E; Cavaletti G; Gasco P; Sancini G
J Control Release; 2017 Mar; 249():103-110. PubMed ID: 28153761
[TBL] [Abstract][Full Text] [Related]
20. Impact of transporters and enzymes from blood-cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake.
Wang Q; Zuo Z
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):961-972. PubMed ID: 30118608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
